La lenta accettazione dei nuovi anticoagulanti orali in Italia: Analisi critica di un problema

Giovanni Luca Botto, Claudio Cuccia, Edoardo Gronda, Federico Lombardi, Maurizio Lunati, Antonio Maggi, Ferdinando Maria Massari, Giuseppe Musumeci, Fabrizio Oliva, Luigi Oltrona Visconti, Cesare Proto, Enrico Pusineri, Walter Ageno

Research output: Contribution to journalReview articlepeer-review

Abstract

The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into clinical practice has revolutionized the prevention and the therapeutic approaches to thromboembolic events in patients with nonvalvular atrial fibrillation and represents with no doubts one of the most remarkable advances in the history of cardiovascular medicine over the last years. NOACs beyond a comparable efficacy with vitamin K antagonists allow to overcome the limitations of this last category of drugs owing to their less drug to drug interactions and a predictable anticoagulant effect that allows a fixed dose administration without the need for continuous monitoring. However, the penetration of NOACs into the Italian market is still lower than predicted with respect to their use in other European countries. The aim of this review is to critically analyze the reasons behind this attitude through the adoption of the nominal group technique, a methodology that permits to reach an official consensus.

Original languageItalian
Pages (from-to)208-218
Number of pages11
JournalGiornale Italiano di Cardiologia
Volume18
Issue number3
Publication statusPublished - Mar 1 2017

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this